Technical Analysis for CKPT - Checkpoint Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 1.89 | -1.56% | -0.03 |
Earnings due: Mar 28
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
50 DMA Resistance | Bearish | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
MACD Bearish Centerline Cross | Bearish | -1.56% | |
NR7 | Range Contraction | -1.56% | |
Narrow Range Bar | Range Contraction | -1.56% | |
Inside Day | Range Contraction | -1.56% | |
Gapped Up | Strength | -1.56% | |
Oversold Stochastic | Weakness | -1.56% | |
50 DMA Resistance | Bearish | 2.16% |
Alert | Time |
---|---|
50 DMA Resistance | about 8 hours ago |
60 Minute Opening Range Breakout | about 8 hours ago |
Up 3% | about 8 hours ago |
Up 2% | about 9 hours ago |
Outside Day | about 12 hours ago |
Get a Trading Assistant
- Earnings date: 03/28/2024
Checkpoint Therapeutics, Inc. Description
Checkpoint Therapeutics, Inc. is an immuno-oncology biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. The Company is engaged in developing a portfolio of human immuno-oncology targeted antibodies. The portfolio of antibodies that it licensed includes antibodies targeting programmed death-ligand 1 (PD-L1), glucocorticoid-induced Tumor necrosis factor receptor (TNFR) related protein (GITR) and carbonic anhydrase IX (CAIX). It focuses on developing the immuno-oncology and checkpoint inhibitor antibodies. It is developing three oral, small molecules, targeted anti-cancer agents, consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Its pipeline of products includes CK-101 and CK-103.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Immunology Immune System Antibodies Cancer Immunotherapy Chemotherapy Epidermal Growth Factor Receptor Immune Checkpoint Solid Tumor Cancers Checkpoint Inhibitor Necrosis Tumor Necrosis Factor Immuno Oncology Biopharmaceutical Tumor Necrosis
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 4.2899 |
52 Week Low | 1.3 |
Average Volume | 596,527 |
200-Day Moving Average | 2.21 |
50-Day Moving Average | 1.98 |
20-Day Moving Average | 2.06 |
10-Day Moving Average | 2.05 |
Average True Range | 0.14 |
RSI (14) | 42.20 |
ADX | 17.88 |
+DI | 19.50 |
-DI | 19.35 |
Chandelier Exit (Long, 3 ATRs) | 1.94 |
Chandelier Exit (Short, 3 ATRs) | 2.27 |
Upper Bollinger Bands | 2.32 |
Lower Bollinger Band | 1.79 |
Percent B (%b) | 0.19 |
BandWidth | 26.02 |
MACD Line | -0.02 |
MACD Signal Line | 0.01 |
MACD Histogram | -0.0337 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 2.10 | ||||
Resistance 3 (R3) | 2.11 | 2.06 | 2.06 | ||
Resistance 2 (R2) | 2.06 | 2.01 | 2.05 | 2.05 | |
Resistance 1 (R1) | 1.98 | 1.98 | 1.95 | 1.96 | 2.04 |
Pivot Point | 1.92 | 1.92 | 1.91 | 1.91 | 1.92 |
Support 1 (S1) | 1.84 | 1.87 | 1.81 | 1.82 | 1.74 |
Support 2 (S2) | 1.78 | 1.84 | 1.78 | 1.73 | |
Support 3 (S3) | 1.70 | 1.78 | 1.72 | ||
Support 4 (S4) | 1.68 |